Home > Gastroenterology > Combination bevacizumab plus atezolizumab may effectively treat some neuroendocrine tumors

Combination bevacizumab plus atezolizumab may effectively treat some neuroendocrine tumors


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 12/04/2022 - In patients with neuroendocrine tumors (NETs), combination therapy with bevacizumab and atezolizumab may improve some outcomes, a nonrandomized trial suggests. "While one small single-arm study cannot and should not change practice, the supportive translational data suggest that we may have the capability of activating the immune system in a subset of patients with NETs, which is quite encouraging," Dr. Daniel Halperin of the University of Texas MD Anderson Cancer Center in Houston told Reuters Health by email. "Fortunately," he added, "there are additional ongoing studies exploring similar approaches, such as NCT03290079 (https://bit.ly/3rik6cs), and we are hopeful that our colleagues will be able to build on the observations we present in this manuscript, so we can continue to move our field toward effective immunotherapy options for our patients." Therapies fo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on